United Therapeutics Corporation (UTHR)
| Market Cap | 8.40B |
| Revenue (ttm) | 1.59B |
| Net Income (ttm) | 470.90M |
| Shares Out | 44.80M |
| EPS (ttm) | 10.25 |
| PE Ratio | 18.25 |
| Forward PE | 11.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 341,402 |
| Open | 187.93 |
| Previous Close | 187.60 |
| Day's Range | 184.31 - 188.30 |
| 52-Week Range | 114.18 - 216.90 |
| Beta | 0.55 |
| Analysts | Buy |
| Price Target | 231.89 (+24.0%) |
| Est. Earnings Date | Nov 3, 2021 |
About UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostini...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is 231.89, which is an increase of 23.96% from the latest price.
News
United Therapeutics to Present New Data at CHEST Annual Meeting 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
7 Top-Rated Pharmaceutical Stocks To Invest in for October
It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first ...
United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics Releases its Annual Corporate Responsibility Report
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients
United Therapeutics Corporation (NASDAQ: UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH). Related ...
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congr...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics (UTHR) Up 3.4% Since Last Earnings Report: Can It Continue?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
Here's Why United Therapeutics Stock May Continue To Trend Higher
The stock price of United Therapeutics, a biotechnology company, has seen a rise of over 15% over the last twenty-one trading days, and it is up a solid 97% over the last twelve-month period. The rally ...
United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASTom...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Con...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up
United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.
Why United Therapeutics Blasted 14% Higher Today
Every one of the company's products booked a revenue gain in Q2.
United Therapeutics (UTHR) Q2 Earnings and Revenues Surpass Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of 27.62% and 17.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics: Q2 Earnings Insights
Shares of United Therapeutics (NASDAQ:UTHR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 11.14% over the past year to $4.09, which beat the e...
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics (UTHR) to Report Q2 Results: Wall Street Expects Earnings Growth
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics Corporation To Report Second Quarter 2021 Financial Results Before The Market Opens On Wednesday,...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
3 LGBTQ+ CEOs Leading Your Investment Portfolio
Pride Month is a good time to be proud of these pioneering corporate leaders.
United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag
United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Applicatio...
DANBURY, Conn., June 16, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics Corporation (Nasdaq: UTHR) reached a major milestone today with the announcement that the U.S. F...
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.
Why Is United Therapeutics (UTHR) Down 8.8% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?